Global Neurostimulation Devices Market Report 2018-2030: Focus on Invasive Devices Such as SCS, DBS, SNS, VNS and Other CNS

Dublin, Oct. 19, 2018 (GLOBE NEWSWIRE) -- The "Neurostimulation Devices Market (2nd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering.

The Neurostimulation Devices Market (2nd Edition), 2018-2030' report features an extensive study of the current landscape and future outlook of the growing market for neurostimulation devices. The focus of this study is on invasive neurostimulation devices, such as devices for spinal cord stimulation (SCS), deep brain stimulation (DBS), spinal nerve stimulation (SNS), vagus nerve stimulation (VNS), other cranial nerve stimulation (Other CNS) and other variants of neurostimulation devices.

The National Academy of Medicine indicates that as many as 100 million people in the US suffer from some form of pain, which has been shown to be associated with a socioeconomic burden of around USD 600 billion per year, in treatment costs and lost productivity. Further, it has been estimated that nearly 1 million people in America suffer from Parkinson's disease, with approximately 60,000 new patients being diagnosed every year.

Over the past few decades, the prevalence of such chronic disorders has grown at an alarming rate. In fact, a recent World Health Organization's Global Burden of Disease study recognized these chronic conditions as one of the leading causes of deteriorating public health in the world. Such clinical conditions have often been shown to result in serious physical, cognitive and psychosocial consequences in patients. This indicates an urgent need for novel and effective treatment methods as the drawbacks of existing treatment options (such as high risk of addiction/abuse associated with long-term use of oral opioids, and complications due to complex surgical procedures) are substantial.

Amongst other elements, the report features:

• A detailed assessment of the overall landscape of neurostimulation devices market, featuring the contributions of various companies engaged in this domain and highlighting key device specifications (size, weight, battery type, battery life, number of electrodes, type of programming, and MRI compatibility), along with information on different types of neurostimulation devices, target therapeutic areas, and regulatory approvals received across various geographies.
• A comprehensive product competitiveness analysis, taking into consideration the supplier power and specific device-related parameters, such as the number of target indications, target nerves, regulatory approvals, and key device specifications.
• Comprehensive profiles of developers of leading neurostimulation devices (shortlisted on the basis of the product competitiveness analysis), featuring an overview of the company, its financial information (if available), and a detailed description of the device(s). Each profile also includes a list of recent developments, highlighting the achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future.
• An elaborate discussion on the regulatory landscape related to medical devices across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific (Australia, China and Japan). The information covers details on the payer mix and the reimbursement processes of various public/private organizations across these geographies.
• A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of product portfolio), highlighting the current perceptions regarding their proprietary brands across different device types, taking into consideration several aspects, such as strength / diversity of product portfolio, extent of patent portfolio, recent collaborations, number of target indications and regulatory approvals, and the overall market positioning of the players.
• An in-depth analysis of the patents that have been published since 2013. The analysis also highlights the key trends associated with these patents, including patent type, regional applicability, CPC classification, IP litigations, emerging areas, leading industry players (in terms of the number of patents filed/granted), and patent benchmarking and valuation.
• A comprehensive clinical trial analysis of completed, ongoing and planned studies of various neurostimulation devices. For the purpose of this analysis, we looked at the clinical studies that have been last updated in 2013, and analyzed them on the basis of various parameters, such as current trial status, regional distribution, leading industry and non-industry players, key indications, and enrolled patient population across different geographies.
• An analysis of the partnerships that have been established in the recent past, covering product development/commercialization agreements, R&D collaborations, technology licensing deals, distribution agreements, mergers/acquisitions, and others.
• An analysis of investments made at various stages of product development/commercialization; these include seed financing, venture capital financing, debt financing and grants/awards received by the companies that are operating in this domain.
• A comprehensive list of non-invasive neurostimulation devices, along with information on their developers, various types of non-invasive technologies used, target therapeutic areas, and development/approval status of the devices.
• An elaborate discussion on the upcoming opportunities/trends in the field of neurostimulation devices that are likely to impact the evolution of this market over the coming years.

One of the key objectives of the report was to estimate the existing market size and potential growth opportunities for neurostimulation devices. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market over the period 2018-2030.

The report provides sales forecasts for the overall neurostimulation devices market with detailed market segmentation on the basis of type neurostimulation devices (SCS, DBS, VNS, and other types), indication (chronic pain, dystonia, epilepsy, essential tremor, heart failure, major depressive disorder, Parkinson's disease, obsessive-compulsive disorder, overactive bladder, sleep apnea), MRI compatibility (MRI compatible and MRI non-compatible), and the geographical distribution of the market (US, Canada, UK, Germany, France, Spain, Italy, Australia, China, and Japan).

In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry's evolution.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Regulatory And Reimbursement Landscape For Medical Devices

5. Current Market Landscape

6. Spinal Cord Stimulation

7. Deep Brain Stimulation

8. Peripheral Nerve Stimulation

9. Brand Positioning Analysis

10. Patent Analysis

11. Clinical Trial Analysis

12. Collaborations And Partnerships

13. Funding And Investment Analysis

14. Market Forecast

15. Future Growth Opportunities

16. Executive Insights

17. Appendix 1: List Of Non-Invasive Neurostimulation Devices

18. Appendix 2: Tabulated Data

19. Appendix 3: List Of Companies And Organizations

• Abbott
• Aberdare Ventures
• Academy Medical Center
• Accelmed Growth Partners
• Action Potential Venture Capital
• AcuKnee
• AdvaStim
• Advent Life Sciences
• Aetion
• Aetna
• AG2R La Mondiale
• Alan Neuromedical Technologies
• ALC Healthcare
• Alere
• Aleva Neurotherapeutics
• Alfred Mann Foundation
• Allergan
• Allianz
• American Academy of Neurology
• American Academy of Pain Medicine
• American Medical Association
• Amzak Health
• Andera Partners
• Anomali
• Antares Capital
• Anthem
• Aperture Venture Partners
• ARAG Group
• Atlante Ventures
• Atrotech
• Attivo Networks
• Aucta Technologies
• Autonomic Technologies
• Autonomix Medical
• Avery Biomedical Devices
• Aviva
• AXA PPP Healthcare
• Axilum Robotics
• Axiobionics
• Axonic Capital
• Axonics Modulation Technologies
• b-to-v Partners
• Banexi Ventures
• Barclays
• Bayer
• BB Biotech Ventures
• BC Platforms
• Becton Dickinson
• Beijing PINS Medical
• Beijing Tiantan Hospital
• Biegler
• BioControl Medical
• BioElectronics
• Bioinduction
• BioMedical Life Systems
• BioMedPartners
• Bioness
• BioScience Managers
• BioWave
• BioWin
• BlueWind Medical
• Boston Scientific
• Brain State Technologies
• Brainlab
• BrainsGate
• BrainsWay
• Bupa
• Cala Health
• Calmare Therapeutics
• Canadian Agency for Drugs and Technologies in Health
• Cancer Prevention and Research Institute of Texas
• Capricorn Venture Partners
• Carbon Black
• Cardionomic
• Carlos III Health Institute
• Case Western Reserve University
• Caser Seguros
• Catholic University of Leuven
• CBC Banque & Assurance
• CEFALY Technology
• Celgene
• CensorNet
• Center for Sensorimotor Neural Engineering
• Centers for Medicare & Medicaid Services
• Centripetal Networks
• Centro of Construction of Cardiac Stimulators of Uruguay
• Cerbomed
• Cerevast Medical
• Certara
• Cervel Neurotech
• Chattem
• Cibiem
• CICA
• Cigna
• Clearly Present Foundation
• Cleveland Clinic
• Clinakos
• Clinigen Group
• Cogentix Medical
• Coridea
• Cormorant Asset Management
• Cosman Medical
• Covidien
• CrowdStrike
• Crdit Mutuel Group
• CVRx
• Cylance
• Darktrace
• Deep Brain Innovations
• Defense Advanced Research Projects Agency
• Deutsche Krankenversicherung
• DEYMED Diagnostic
• Dolphin Neurostim
• Dr. Langer Medical
• DyAnsys
• EaglePicher Medical Power
• EBS Technologies
• electroCore
• ElectroMedical Technologies
• Electronic Waveform Lab
• Elron Electronic Industries
• ELvation
• Endeavour Vision
• Endonovo Therapeutics
• EndoStim
• eNeura
• Enopace Biomedical
• Enspire DBS Therapy
• Epimed International
• ERGO Group
• Evergreen Medical Technologies
• Evidera
• Exabeam
• Expatriate Healthcare
• F3F
• Federal Holding and Investment Company
• Finetech Medical
• FireEye
• Firstkind
• Fisher Wallace Laboratories
• Flashpoint
• Flatiron Health
• Flow Neuroscience
• Fogarty Institute for Innovation
• Forbion Capital Partners
• Forrestal Capital
• Fortinet
• Fountain Healthcare Partners
• Freedom Health
• French National Authority for Health
• Frontcourt Ventures
• Functional Neuromodulation
• FundRx
• Gala Therapeutics
• Galvani Bioelectronics
• Generali Deutschland
• German Institute of Medical Documentation and Information
• Gigamon
• Gilde Healthcare Partners
• GiMer Medical
• Gimv
• GlaxoSmithKline
• Gradient Medical
• Greatbatch
• Green Park & Golf Ventures
• GTX Medical
• Hannover Re
• HBM Healthcare Investments
• HealthCore
• Helius Medical Technologies
• Helpucover
• HiDow
• High-Tech Grnderfonds
• Hollywog
• Horowitz Group
• Humana
• Humanitas Clinical Institute
• ICON
• INC Research
• InCube Labs
• Indegene
• IndependiCare
• Ingress Health
• Initiative Capital Romandie
• INKEF Capital
• Innogest Capital
• Innovative Health Solutions
• Inspire Medical Systems
• Institute for Hospital Remuneration System
• Institute for Industrial Science
• Institute for Quality and Efficiency in Health Care
• Institute of Hospitalization and Care of Scientific Character
• Institute of Medical Arts
• InterWest Partners
• InterX Technologies
• IntraPace
• IPF Partners
• IQVIA
• iTENS
• Johari Digital Healthcare
• Johnson & Johnson
• JumpStart
• Kairuku
• Kaiser Permanente
• KCK Group
• Kinled Holding
• Kleiner Perkins
• La Luxembourgeoise
• LABORIE Medical Technologies
• Legend Capital Management
• Leonite Capital
• Lightstone Ventures
• Linguamatics
• LivaNova
• LogRhythm
• Lone Star Neuromodulation
• Longitude Capital
• LSP
• Lungpacer Medical
• MAAF Assurances
• MAG & More
• Magstim
• MagVenture
• Mainstay Medical
• Massachusetts Life Science Center
• Mayo Clinic
• Mayo Foundation for Medical Education and Research
• McAfee
• McKesson
• MDC Partners
• Meagan Medical
• Med-Ally
• Medaffcon
• Medi-Line
• Medical University of South Carolina
• Medicines and Healthcare products Regulatory Agency
• Medisana
• MedSec
• Medtronic
• MEMStim
• Mercy
• Metavention
• Micro-Leads
• MicroTransponder
• Minnetronix
• Morgenthaler
• Munich Re
• MyndTec
• National Agency for Medicines and Health Products Safety
• National Engineering Laboratory for Neuromodulation
• National Institute of Excellence in Health and Social Services
• National Institute of Health and Clinical Excellence
• National Institute of Medical Sciences and Nutrition Salvador Zubiran
• National Institutes of Health
• National Neuroscience Institute
• Nature's Gate
• NeoMed Management
• NeoSync
• Nervana Systems
• Netherlands Enterprise Agency
• Neuralieve
• neuroCare
• Neuroelectrics
• NeuroEM Therapeutics
• NeuroHabilitation
• NeuroMetrix
• Neuromod
• Neuronetics
• NeuroOne Medical Technologies
• NeuroPace
• NeuroQore
• NeuroRecovery Technologies
• Neuros Medical
• NeuroSigma
• NeuroTek Medical
• Neurova
• Neurowave Medical Technologies
• Nevro
• New Enterprise Associates
• Newronika
• Newton Biocapital
• Nexeon MedSystems
• Nexstim
• Nia Therapeutics
• Niveus Medical
• Novallia
• Novartis
• NTLab
• Nuvectra
• Nyxoah
• Ohio Third Frontier
• OMRON Healthcare
• OrbiMed Advisors
• Oregon Health & Science University
• Orthofix
• Osage University Partners
• Ottobock
• Oxford Finance
• Pain Alliance Europe
• PainPod BioTechnology
• Palantir
• Palo Alto Networks
• Parasym Health
• PAREXEL
• PathMaker Neurosystems
• PerkinElmer
• Pharmaceuticals and Medical Devices Agency
• PhysIOL
• Ping An Insurance
• PlatoScience
• Presidio Partners
• Principia SGR
• Prizm Medical
• ProtectWise
• Rainbow Medical
• Reeve Foundation
• Regional investment Company of Wallonia
• RenalGuard Solutions
• Renewal Technologies
• ReShape Lifesciences
• Respicardia
• RITM
• Ritmedic
• Saama Technologies
• Saga Health Insurance
• Saluda Medical
• Samsung Electronics America
• Sanderling Ventures
• Sanitas
• Sant Ventures
• Sapiens Steering Brain Stimulation
• Scion NeuroStim
• SegurCaixa Adeslas
• Sensory NeuroStimulation
• SetPoint Medical
• Shape Security
• SHYFT Analytics
• Siemens
• Silicon Valley Bank
• Silk'n Therapy
• Smiths Medical
• Sofinnova Partners
• Sophos
• Soterix Medical
• Southern California Permanente Medical Group
• SPR Therapeutics
• St. Jude Medical (Abbott)
• StimGuard
• StimRelieve
• Stimwave
• SUBLIMED
• SUNMAS
• Synapse Biomedical
• Synergia Medical
• Syntilla Medical
• Tal Medical
• Tempus
• TENS Rx
• Theranica Bio-Electronics
• Threat Stack
• Thync
• Topspin Partners
• TraceSecurity
• Trustwave
• Tsinghua University
• TYRX
• Ultra Care Systems
• UnitedHealthcare
• University of Brussels
• University of California
• University of Milan
• University of Minnesota
• University of New Mexico
• University of Pittsburgh
• University of Tokyo
• University of Washington
• US Department of Defense
• US Department of Homeland Security
• US Venture Partners
• USCI Japan
• VA Office of Research and Development
• Valencia Technologies
• Valtronic
• Vectra Networks
• Vention
• Venture Bank
• Versant Ventures
• Virility Medical
• Vision Sciences
• Vital Motion
• VitalityHealth
• Wellington Partners
• Windham Venture Partners
• Wisconsin Alumni Research Foundation
• WISE
• Xavant Technology
• Yongjin Group
• Ysios Capital Partners
• Zenedge
• Zephyr Health
• ZOLL Medical
• ZTE
• Zynex Medical

For more information about this report visit https://www.researchandmarkets.com/research/8jq7gh/global?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Neurology Devices